ALNY Stock Forecast: Alnylam Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$144
−2.85% on the day

The 30 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. hold a median 12-month price target of $287 — +99.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 58 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$19.3B
Ticker Nerd rank
58/ 100
Median analyst target
$287
Analysts covering
30
Revenue$1.3B+66.9% y/y
Operating income$231.4M
Net income$164.5M
Free cash flow$292.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.0%
1M
−37.8%
YTD
−63.9%
1Y
−67.8%
From 52W high
−69.7%
From 52W low
0.0%
$144
$473
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Alnylam Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
58/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Growth
95
Quality
94
Volatility
79
Revisions
68
Issuance
31
Momentum
11
Accruals
10

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALNY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALNY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$100$200$300$400$500Jan 26Apr 26Jul 26Oct 26ALNYHigh $410Median $287Low $180

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says30 analysts
21
Buy
9
Hold
0
Sell
$180
Low
$287
Median
$410
High

The green dot is the last close — the median target sits +99.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 18 moved it down.

DateFirmActionRatingTarget
20 Nov 2026BMO CapitalMaintainsOutperform$292 → $293
17 Nov 2026Cantor FitzgeraldMaintainsNeutral$290 → $205
17 Nov 2026HC Wainwright & Co.MaintainsBuy$455 → $250
2 Nov 2026BarclaysMaintainsOverweight$450 → $380
2 Nov 2026Canaccord GenuityMaintainsBuy$429 → $323
2 Nov 2026Truist SecuritiesDowngradeHold$315 → $225
31 Oct 2026UBSMaintainsBuy—
30 Oct 2026BernsteinDowngradeMarket Perform$376 → $199
30 Oct 2026Goldman SachsMaintainsBuy$536 → $320
30 Oct 2026Morgan StanleyMaintainsEqual-Weight$300 → $240
30 Oct 2026Raymond JamesDowngradeOutperform$420 → $315
30 Oct 2026RBC CapitalMaintainsOutperform$345 → $280
30 Oct 2026TD CowenMaintainsBuy$482 → $354
30 Oct 2026UBSMaintainsBuy$354 → $329
30 Oct 2026Wells FargoMaintainsEqual-Weight$253 → $220
29 Oct 2026NeedhamMaintainsBuy$357 → $243
15 Oct 2026UBSAssumesBuy$550 → $354
14 Oct 2026CitigroupMaintainsBuy$340 → $320
14 Oct 2026Wells FargoMaintainsEqual-Weight$256 → $253
8 Oct 2026RBC CapitalMaintainsOutperform$350 → $345

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALNY.

Market Radar

This page is one stock. Monday covers all of them.

ALNY appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALNY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Alnylam Pharmaceuticals, Inc. returned −67.8% against +6.9% for the S&P 500, dividends included.

ALNY vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26ALNYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALNY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+154.4%
Analysts raising
11
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.5×

Cheaper than 81% of US stocks

Price / sales
3.8×

Cheaper than 28% of US stocks

Price / book
5.3×

Cheaper than 17% of US stocks

EV / EBITDA
18.1×

Cheaper than 24% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
640.5%

Higher than 96% of US stocks

Gross margin
76.9%

Higher than 89% of US stocks

Operating margin
19.5%

Higher than 79% of US stocks

Net margin
—
Returns & dividend
Return on equity
138.1%

Higher than 97% of US stocks

Return on assets
9.5%

Higher than 91% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alnylam Pharmaceuticals, Inc. has a market value of $19.3B and an enterprise value of $18.7B.

  • Revenue in the twelve months to 30 June 2026: $4.8B. The latest quarter grew 66.9% year on year.

  • Net income over the same four quarters: $808.0M, a 16.8% net margin.

  • Diluted earnings per share, trailing twelve months: $5.38.

  • Free cash flow in the twelve months to 30 June 2026: $819.9M.

  • Shares outstanding: 133.7M.

  • Trailing P/E: 7.5×; forward P/E: 14.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alnylam Pharmaceuticals, Inc. employs 2,500 people — $1.9M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ALNY and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALNYAlnylam Pharmaceuticals, Inc.$19.3B58
ASNDAscendis Pharma A/S$16.6B93
INCYIncyte Corp.$22.9B89
EXELExelixis, Inc.$15.8B100
BBIOBridgeBio Pharma, Inc.$14.7B80
JAZZJazz Pharmaceuticals Plc$14.4B95
ROIVRoivant Sciences Ltd.$27.7B83

Take a look at ALNY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Alnylam Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ALNY

What is the ALNY stock price forecast for 2026-2027?

The 30 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. have a median 12-month price target of $287, with estimates ranging from $180 to $410. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALNY stock a buy right now?

Of the 30 analysts covering Alnylam Pharmaceuticals, Inc., 21 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alnylam Pharmaceuticals, Inc. 58 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALNY?

As at 21 Nov 2026, Alnylam Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will ALNY stock go up?

No one can know that. What the data says: the median 12-month target from 30 analysts implies +99.8% from the last close, and Ticker Nerd's factor model ranks Alnylam Pharmaceuticals, Inc. 58 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALNY stock forecast for 2030?

No analyst covering Alnylam Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $180 to $410 over the next 12 months.

How has ALNY stock performed over the past year?

Alnylam Pharmaceuticals, Inc. returned -67.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alnylam Pharmaceuticals, Inc. do?

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions.

Company

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio includes approved therapies for transthyretin-mediated amyloidosis, and the company also advances programs in areas such as hypertension and other genetically defined diseases. Alnylam Pharmaceuticals works across the United States, Europe, and other international markets, supporting patients through specialized treatments and healthcare partnerships. Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals plays a significant role in the growing RNAi medicine segment, where it is recognized for translating gene-silencing science into commercial therapies for serious conditions.

CEO Dr. Yvonne L. Greenstreet M.B.A., M.D. · 2,500 employees · United States · https://www.alnylam.com